This IgG exhibits a unique sialylation modification at Asn162 of CH1 and is widely expressed in cancer stem cells of epithelial carcinomas, where it promotes tumor progression via activation of the integrin-FAK signaling pathway (56). The gene discussed is PTK2; the disease is neoplasm.